Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Patient and control characteristics at baseline a

From: High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study

Characteristics at time of inclusion Controls All RA patients DMARD-naïve patients TNFi-naïve patients TNFi ongoing Baseline TNFi introduction
(N = 31) (N = 96) (N = 18) (N = 58) (N = 21) (N = 21)
Monoclonal antibodies/soluble receptors (n) 12/9 10/11
Females (%) 68 71 78 71 76 75
Age, yr (mean ± SD) 51 ± 16 59 ± 13 59 ± 16 58 ± 14 59 ± 11 59 ± 11
RA duration, yr (median (IQR)) 10 (4 to 21) 4 (3 to 19) 8 (3 to 22) 9 (5 to 16) 7 (2 to 28)
RF positivity (%) 76 76 68 80 81
ACPA positivity (%) 76 76 71 74 71
RF- and ACPA-negative (%)   21 22 21 19 19
Radiographic erosions (%) 73 65 67 81 71
Ongoing synthetic DMARD (%) 69 0 46 71 77
Previous TNFi (%) 36 0 0 86 0
Previous use of other biologic drugs (n) 40 0 0 19 0
Use of steroids (<10 mg/day) (%) 0 60.4 50.0 53.3 66.6 54.5
Current steroid dose (mg/day) 0 5 (0 to 9) 2.5 (0 to 7.8) 2.5 (0 to 7.6) 5.5 (0 to 8.6) 5 (0 to 9.2)
C-reactive protein level (mg/dl) 1.1 (0.4 to 2.4) 0.8 (0.3 to 2.8) 0.9 (0.4 to 1.9) 1.9 (0.8 to 2.8) 1.4 (0.4 to 2.6)
DAS28 score (median (IQR)) 4.2 (3.4 to 5.5) 4.2 (3.4 to 5.0) 3.9 (3.3 to 4.7) 5.7 (5.1 to 6.4) 4.5 (2.8 to 5.0)
  1. aACPA, Anticitrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; DMARD, Disease-modifying antirheumatic drug; RA, Rheumatoid arthritis; RF, Rheumatoid factor; TNFi, Tumor necrosis factor inhibitor. DMARD-naïve patients and patients at baseline of TNFi introduction are included in the TNFi-naïve patient group. TNFi ongoing patients are different from all the other subgroups. All analyses are adjusted for age, sex and glucocorticoid dose.